8 April 2024 - Dovato is now the first and only oral, two drug, single-tablet regimen available for people aged 12 and older living with HIV, a population in need of additional treatment options.

ViiV Healthcare today announced the US FDA approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.

Read ViiV press release